SGLT2阻害薬がもたらす心不全治療ストラテジーの変革

出版社： 先端医学社
著者：
発行日： 2023-03-01
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784865505757
電子書籍版： 2023-03-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

6,050 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,235 円(税込)

購入する

商品紹介

SGLT2阻害薬を筆頭に心不全治療におけるFantastic Fourの解説を施した、ストラテジーシリーズ最新刊!
わが国では現在、“心不全パンデミック”と称される状態に陥っている。患者のQOLを損なわないために、心不全に対する取り組み強化は重要である。薬物治療は心不全治療の根幹であり、とくにSGLT2阻害薬はHFpEFにも有効性を示したことがあげられる。心不全におけるSGLT2阻害薬治療に焦点を当てた一冊。

目次

  • 第1章：わが国における心不全治療の現状を探る
    第2章：心不全の病態を探る
    第3章：心不全の診断と治療の考え方を探る
    第4章：SGLT2阻害薬の薬理作用と多因子介入による効果を探る
    第5章：SGLT2阻害薬による心不全の予防と治療のストラテジーを探る
    第6章：SGLT2阻害薬を使用する際の注意点を探る
    第7章：SGLT2阻害薬による心不全治療の今後の展望をみる

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 : わが国における心不全治療の現状を探る

P.5 掲載の参考文献
1) GBD 2017 Disease and Injury Incidence and Prevalence Collaborators : Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392 : 1789-1858, 2018
 
2) Tsao CW, Aday AW, Almarzooq ZI et al : Heart disease and stroke statistics-2022 update : a report from the American Heart Association. Circulation 145 : e153-e639, 2022
PubMed
3) Okura Y, Ramadan MM, Ohno Y et al : Impending epidemic : future projection of heart failure in Japan to the year 2055. Circ J 72 : 489-491, 2008
 
4) 日本循環器学会 : 2015年・2019年循環器疾患診療実態調査報告書
 
5) Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S et al : Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70 : 1617-1623, 2006
PubMed
6) Shiba N, Watanabe J, Shinozaki T et al : Analysis of chronic heart failure registry in the Tohoku district : third year follow-up. Circ J 68 : 427-434, 2004
PubMed
7) Shiba N, Nochioka K, Miura M et al : Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan--first report from the CHART-2 study. Circ J 75 : 823-833, 2011
PubMed
8) Sato N, Kajimoto K, Keida T et al : Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77 : 944-951, 2013
PubMed
9) Ide T, Kaku H, Matsushima S et al : Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese registry of acute decompensated heart failure (JROADHF). Circ J 85 : 1438-1450, 2021
PubMed
10) Owan TE, Hodge DO, Herges RM et al : Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 : 251-259, 2006
PubMed
11) 厚生労働省 : 令和2年 (2020) 人口動態統計 (確定数) の概況
 
12) Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) : The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction : an individual patient data meta-analysis. Eur Heart J 33 : 1750-1757, 2012
 
13) Tsuji K, Sakata Y, Nochioka K et al : Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 19 : 1258-1269, 2017
 
P.10 掲載の参考文献
1) Bozkurt B, Coats AJ, Tsutsui H et al : Universal definition and classification of heart failure : a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 27 : 387-413, 2021
 
2) 日本循環器学会, 日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版), 2018
 
3) McDonagh TA, Metra M, Adamo M et al : 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
PubMed
4) Heidenreich PA, Bozkurt B, Aguilar D et al : 2022 AHA/ACC/HFSA Guideline for the management of heart failure : a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145 : e895-e1032, 2022
 
5) Ammar KA, Jacobsen SJ, Mahoney DW et al : Prevalence and prognostic significance of heart failure stages : application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 115 : 1563-1570, 2007
 
6) Vasan RS, Levy D : Defining diastolic heart failure : a call for standardized diagnostic criteria. Circulation 101 : 2118-2121, 2000
 
7) Reddy YNV, Carter RE, Obokata M et al : A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138 : 861-870, 2018
PubMed
8) Pieske B, Tschope C, de Boer RA et al : How to diagnose heart failure with preserved ejection fraction : the HFA-PEFF diagnostic algorithm : a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 22 : 391-412, 2020
 
9) Solomon SD, Vaduganathan M, L Claggett B et al : Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141 : 352-361, 2020
PubMed
10) Halliday BP, Wassall R, Lota AS et al : Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF) : an open-label, pilot, randomised trial. Lancet 39. 3 : 61-73, 2019
 

第2章 : 心不全の病態を探る

P.18 掲載の参考文献
1) McMurray JJV, Solomon SD, Inzucchi SE et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
2) Packer M, Anker SD, Butler J et al : Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383 : 1413-1424, 2020
PubMed
3) Thrainsdottir IS, Aspelund T, Thorgeirsson G et al : The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 28 : 612-616, 2005
PubMed
4) Shimizu I, Minamino T, Toko H et al : Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 120 : 1506-1514, 2010
PubMed
5) Lu S, Liao Z, Lu X et al : Hyperglycemia acutely increases cytosolic reactive oxygen species via O-linked GlcNAcylation and CaMK II activation in mouse ventricular myocytes. Circ Res 126 : e80-e96, 2020
 
6) Hartog JW, Voors AA, Bakker SJ et al : Advanced glycation end-products (AGEs) and heart failure : pathophysiology and clinical implications. Eur J Heart Fail 9 : 1146-1155, 2007
PubMed
7) Boudina S, Abel ED : Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11 : 31-39, 2010
PubMed
8) Hammer S, Snel M, Lamb HJ et al : Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 52 : 1006-1012, 2008
PubMed
9) Sacks HS, Fain JN : Human epicardial adipose tissue : a review. Am Heart J 153 : 907-917, 2007
PubMed
10) Zhong J, Maiseyeu A, Davis SN et al : DPP4 in cardiometabolic disease : recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 116 : 1491-1504, 2015
PubMed
11) dos Santos L, Salles TA, Arruda-Junior DF et al : Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail 6 : 1029-1038, 2013
PubMed
12) Nakajima Y, Ito S, Asakura M et al : A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats. J Mol Cell Cardiol 129 : 257-265, 2019
PubMed
13) Muller TD, Finan B, Bloom SR et al : Glucagon-like peptide 1 (GLP-1). Mol Metab 30 : 72-130, 2019
PubMed
14) Scirica BM, Bhatt DL, Braunwald E et al : Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 : 1317-1326, 2013
PubMed
15) White WB, Cannon CP, Heller SR et al : Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 : 1327-1335, 2013
PubMed
16) Rosenstock J, Perkovic V, Johansen OE et al : Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk : the CARMELINA randomized clinical trial. JAMA 321 : 69-79, 2019
PubMed
17) Margulies KB, Hernandez AF, Redfield MM et al : Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction : a randomized clinical trial. JAMA 316 : 500-508, 2016
PubMed
18) Packer M : Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials. Circ Res 122 : 928-932, 2018
PubMed
19) Gerstein HC, Colhoun HM, Dagenais GR et al : Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) : a double-blind, randomised placebo-controlled trial. Lancet 394 : 121-130, 2019
PubMed
20) Gerstein HC, Sattar N, Rosenstock J et al : Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385 : 896-907, 2021
PubMed
21) Dunlay SM, Givertz MM, Aguilar D et al : Type 2 Diabetes mellitus and heart failure : a scientific statement from the American Heart Association and the Heart Failure Society of America : this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 140 : e294-e324, 2019
 
22) Opie LH : The metabolic vicious cycle in heart failure. Lancet 364 : 1733-1734, 2004
PubMed
P.25 掲載の参考文献
1) Nagoshi T, Yoshimura M, Rosano GM et al : Optimization of cardiac metabolism in heart failure. Curr Pharm Des 17 : 3846-3853, 2011
PubMed
2) Lam CSP, Butler J : Victims of success in failure. Circulation 142 : 1129-1131, 2020
PubMed
3) Tsutsui H, Ide T, Ito H et al : JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. J Card Fail 27 : 1404-1444, 2021
PubMed
4) Kashiwagi Y, Nagoshi T, Yoshino T et al : Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice. PLoS One 10 : e013060S, 2015
PubMed
5) Yoshii A, Nagoshi T, Kashiwagi Y et al : Cardiac ischemia-reperfusion injury under insulin-resistant conditions : SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. Cardiovasc Diabetol 18 : 85, 2019
PubMed
6) Kimura H, Nagoshi T, Oi Y et al : Treatment with atrial natriuretic peptide induces adipose tissue browning and exerts thermogenic actions in vivo. Sci Rep 11 : 17466, 2021
PubMed
7) Kang R, Nagoshi T, Kimura H et al : Possible association between body temperature and B-type natriuretic peptide in patients with cardiovascular diseases. J Card Fail 27 : 75-82, 2021
 
P.28 掲載の参考文献
1) 2021年JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療, 2021
Medical*Online
2) Heidenreich PA, Bozkurt B, Aguilar D et al : 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145 : e895-e1032, 2022
 
3) Steinberg BA, Zhao X, Heidenreich PA et al : Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction : prevalence, therapies, and outcomes. Circulation 126 : 65-75, 2012
PubMed
4) Kinugasa Y, Yamamoto K : The challenge of frailty and sarcopenia in heart failure with preserved ejection fraction. Heart 103 : 184-189, 2017
PubMed
5) Tsuji K, Sakata Y, Nochioka K et al : Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study. Eur J Heart Fail 19 : 1258-1269, 2017
 
6) Reddy YNV, Obokata M, Verbrugge FH et al : Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation. J Am Coll Cardiol 76 : 1051-1064, 2020
 
7) Borlaug BA, Blair J, Bergmann MW et al : Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation 145 : 1592-1604, 2022
PubMed
8) Shah SJ, Kitzman DW. Borlaug BA et al : Pheno-type-specific treatment of heart failure with preserved ejection fraction : a multiorgan roadmap. Circulation 134 : 73-90, 2016
 
9) Owan TE, Hodge DO, Herges RM et al : Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 : 251-259, 2006
PubMed
10) Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S et al : Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1893-1900, 2009
PubMed
11) Hamaguchi S, Kinugawa S, Sobirin MA et al : Mode of death in patients with heart failure and reduced vs. preserved ejection fraction : report from the registry of hospitalized heart failure patients. Circ J 76 : 1662-1669, 2012
PubMed
P.33 掲載の参考文献
1) Damman K, Valente MA, Voors AA et al : Renal impairment, worsening renal function, and outcome in patients with heart failure : an updated meta-analysis. Eur Heart J 35 : 455-469, 2013
PubMed
2) Ronco C, Haapio M, House AA et al : Cardiorenal syndrome. J Am Coll Cardiol 52 : 1527-1539, 2008
PubMed

第3章 : 心不全の診断と治療の考え方を探る

P.39 掲載の参考文献
1) Braunwald E : Biomarkers in heart failure. Preface. Heart Fail Clin 5 : xiii-xiv, 2009
PubMed
2) Dhingra R, Vasan RS : Biomarkers in cardiovascular disease : statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med 27 : 123-133, 2017
PubMed
3) Yamamoto K, Burnett JC Jr, Jougasaki M et al : Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 : 988-994, 1996
PubMed
4) Nakamura M, Endo H, Nasu M et al : Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 87 : 131-135, 2002
 
5) Maisel AS, Krishnaswamy P, Nowak RM et al : Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 : 161-167, 2002
PubMed
6) Le Jemtel TH, Padeletti M, Jelic S : Diagnosticand therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 49 : 171-180, 2007
 
7) Rutten FH, Cramer MJ, Grobbee DE et al : Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 26 : 1887-1894, 2005
PubMed
8) Harjola VP, Parissis J, Brunner-La Rocca HP et al : Comprehensive in-hospital monitoring in acute heart failure : applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart Fail 20 : 1081-1099, 2018
 
9) Troughton RW, Frampton CM, Brunner-La Rocca HP et al : Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization : an individual patient meta-analysis. Eur Heart J 35 : 1559-1567, 2014
PubMed
10) Lam CSP, Li YH, Bayes-Genis A et al : The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. J Chin Med Assoc 82 : 447-451, 2019
 
11) Hamatani Y, Nagai T, Shiraishi Y et al : Long-term prognostic significance of plasma B-type natriuretic peptide level in patients with acute heart failure with reduced, mid-range, and preserved ejection fractions. Am J Cardiol 121 : 731-738, 2018
PubMed
12) Rorth R, Jhund PS, Kristensen SL et al : The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail 21 : 40-49, 2019
 
13) Aimo A, Januzzi JL Jr, Vergaro G et al : Prognostic value of high-sensitivity troponin T in chronic heart failure : an individual patient data meta-analysis. Circulation 137 : 286-297, 2018
PubMed
14) Packer M, McMurray JJ, Desai AS et al : Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 6 : 54-61, 2015
 
15) Vodovar N, Seronde MF, Laribi S et al : Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail 3 : 629-636, 2015
PubMed
16) Januzzi JL Jr, Zannad F, Anker SD et al : Prognostic importance of NT-proBNP and effect of empagliflozin in the EMPEROR-Reduced trial. J Am Coll Cardiol 78 : 1321-1332, 2021
 
17) Lee MMY, Brooksbank KJM, Wetherall K et al : Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143 : 516-525, 2021
PubMed
18) Damman K, Beusekamp JC, Boorsma EM et al : Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 22 : 713-722, 2020
PubMed
P.44 掲載の参考文献
1) Solomon SD, Vaduganathan M, L Claggett B et al : Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141 : 352-361. 2020
PubMed
2) Clelarld JGF, Bunting KV, Flather MD et al : Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction : an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39 : 26-35, 2018
 
3) Lund LH, Claggett B, Liu J et al : Heart failure with mid-range ejection fraction in CHARM : characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20 : 1230-1239, 2018
PubMed
4) Vaduganathan M, Jhund PS, Claggett BL et al : A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur Heart J 41 : 2356-2362, 2020
PubMed
5) Solomon SD, Claggett B, Lewis EF et al : Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37 : 455-462, 2016
PubMed
6) Butler J, Packer M, Filippatos G et al : Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43 : 416-426, 2022
PubMed
7) Teerlink JR, Diaz R, Felker GM et al : Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALAC-TIC-HF. J Am Coll Cardiol 78 : 97-108, 2021
 
8) Dewan P, Jackson A, Lam CSP et al : Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. Eur J Heart Fail 22 : 898-901, 2020
PubMed
9) Savarese G, Vedin O, D'Amario D et al : Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail 7 : 306-317, 2019
PubMed
10) Kanzaki M, Asano Y, Ishibashi-Ueda H et al : A development of nucleic chromatin measurements as a new prognostic marker for severe chronic heart failure. PLoS One 11 : e0148209, 2016
 
11) Ko T, Fujita K, Nomura S et al : Quantification of DNA damage in heart tissue as a novel prediction tool for therapeutic prognosis of patients with dilated cardiomyopathy. JACC Basic Transl Sci 4 : 670-680, 2019
PubMed
12) Saito T, Asai K, Sato S et al : Ultrastructural features of cardiomyocytes in dilated cardiomyopathy with initially decompensated heart failure as a predictor of prognosis. Eur Heart J 36 : 724-732, 2015
PubMed
13) Nakata T, Nakajima K, Yamashina S et al : A pooled analysis of multicenter cohort studies of 123I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 6 : 772-784, 2013
 
14) Chimura M, Ohtani T, Sera F et al : Focal severe decrease in myocardial technetium-99 m sestamibi uptake indicates ventricular irreversibility in patients with dilated cardiomyopathy. Ann Nucl Med 35 : 881-888, 2021
PubMed
15) Takeda Y, Sakata Y, Mano T et al : Noninvasive assessment of diastolic function in subjects with preserved left ventricular ejection fraction : usefulness of color kinetic imaging. J Card Fail 14 : 569-576, 2008
PubMed
16) Ohtani T, Mohammed SF, Yamamoto K et al : Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur Heart J 33 : 1742-1749, 2012
PubMed
17) Su MY, Lin LY, Tseng YH et al : CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging 7 : 991-997, 2014
PubMed
18) Chimura M, Ohtani T, Tsukamoto Y et al : Ratio of pulmonary artery diameter to ascending aortic diameter and severity of heart failure. J Heart Lung Transplant 37 : 1341-1350, 2018
PubMed
P.49 掲載の参考文献
1) 2021年JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療
Medical*Online
2) McDonagh TA, Metra M, Adamo M et al : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
PubMed
3) Heidenreich PA, Bozkurt B, Aguilar D et al : 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79 : e263-e421, 2022
 
4) Anker SD, Butler J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed

第4章 : SGLT2 阻害薬の薬理作用と多因子介入による効果を探る

P.56 掲載の参考文献
1) Braunwald E : Gliflozins in the management of cardiovascular disease. N Engl J Med 386 : 2024-2034, 2022
PubMed
2) Marton A, Kaneko T, Kovalik JP et al : Organ protection by SGLT2 inhibitors : role of metabolic energy and water conservation. Nat Rev Nephrol 17 : 65-77, 2021
PubMed
3) Fathi A, Vickneson K, Singh JS : SGLT2-inhibitors ; more than just glycosuria and diuresis. Heart Fail Rev 26 : 623-642, 2021
PubMed
4) Cefalu WT, Leiter LA, Yoon KH et al : Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU) : 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382 : 941-950, 2013
PubMed
5) Zou X, Shi Q, Vandvik PO et al : Sodium-glucose cotransporter-2 inhibitors in patients with heart failure : a systematic review and meta-analysis. Ann Intern Med 175 : 851-861, 2022
PubMed
6) Mordi NA, Mordi IR, Singh JS et al : Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure : the RECEDE-CHF trial. Circulation 142 : 1713-1724, 2020
PubMed
7) Voors AA, Angermann CE, Teerlink JR et al : The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure : a multinational randomized trial. Nat Med 28 : 568-574, 2022
PubMed
8) Neuen BL, Oshima M, Agarwal R et al : Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes : a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145 : 1460-1470, 2022
PubMed
9) 日本糖尿病・生活習慣病ヒューマンデータ学会糖尿病標準診療マニュアル作成委員会 : 糖尿病標準診療マニュアル 2022 (一般診療所・クリニック向け), 2022. (2023年4月に改訂版発行予定. http://human-data.or.jp)
 
P.60 掲載の参考文献
Zelniker TA, Braunwald E : Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors : JACC state-of-the-art review. J Am Coll Cardiol 75 : 422-434, 2020
PubMed
Heerspink HJ, Perkins BA, Fitchett DH et al : Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus : cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 : 752-772, 2016
PubMed
Rangaswami J, Bhalla V, de Boer IH et al : Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease : a scientific statement from the American Heart Association. Circulation 142 : e265-e286, 2020
PubMed
P.65 掲載の参考文献
1) Heerspink HJ, Perkins BA, Fitchett DH et al : Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus : cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 : 752-772, 2016
PubMed
2) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
3) Verma S, McMurray JJV : SGLT2 inhibitors and mechanisms of cardiovascular benefit : a state-of-the-art review. Diabetologia 61 : 2108-2117, 2018
PubMed
4) Sano M : A new class of drugs for heart failure : SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol 71 : 471-476, 2018
 
5) Inzucchi SE, Zinman B, Fitchett D et al : How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41 : 356-363, 2018
PubMed
6) Li J, Woodward M, Perkovic V et al : Mediators of the effects of Canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Fail 8 : 57-66, 2020
PubMed
7) Tanaka A, Node K : Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. J Cardiol 69 : 501-507, 2017
PubMed
8) Matsuba R, Matsuba I, Shimokawa M et al : Tofogliflozin decreases body fat mass and improves peripheral insulin resistance. Diabetes Obes Metab 20 : 1311-1315, 2018
PubMed
9) Hattori Y : Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors : proposed role of ketone utilization. Heart Fail Rev 25 : 403-408, 2020
PubMed
10) Zelniker TA, Braunwald E : Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors : JACC state-of-the-art review. J Am Coll Cardiol 75 : 422-434, 2020
PubMed
11) Lahnwong S, Chattipakorn SC, Chattipakorn N : Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardiovasc Diabetol 17 : 101, 2018
PubMed
12) Trum M, Riechel J, Lebek S et al : Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes. ESC Heart Fail 7 : 4429-4437, 2020
PubMed
13) Tanaka A, Node K : Cardiovascular surrogate markers and cardiometabolic therapeutics : a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol 20 : 41, 2021
PubMed
14) Tanaka A, Hisauchi I, Taguchi I et al : Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure : a randomized trial (CANDLE). ESC Heart Fail 7 : 1585-1594, 2020
PubMed
15) Tanaka A, Shimabukuro M, Teragawa H et al : Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease : a secondary analysis of the placebo-controlled, randomized EMBLEM trial. Cardiovasc Diabetol 20 : 105, 2021
PubMed
16) Tanaka A, Node K : Natriuretic peptide-based risk prediction and assessment of treatment effect : revisited in this era. JACC Heart Fail 9 : 941-942, 2021
PubMed
17) Tanaka A, Node K : How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition? Cardiovasc Diabetol 19 : 206, 2020
 
18) Tanaka A, Shimabukuro M, Machii N et al : Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease : results from the multicenter, randomized, placebo-controlled, double-blind EMBLEM trial. Diabetes Care 42 : e159-e161, 2019
PubMed
19) Tanaka A, Shimabukuro M, Machii N et al : Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases : the placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus : multi-center placebo-controlled double-blind randomized trial. J Diabetes Investig 11 : 1551-1563, 2020
 
20) Tanaka A, Teragawa H, Takamura T et al : Effect of add-on empagliflozin on arterial stiffness in patients with type 2 diabetes and cardiovascular disease : an analysis from the placebo-controlled EMBLEM trial. Vasc Fail, 2022. in press
 

第5章 : SGLT2 阻害薬による心不全の予防と治療のストラテジーを探る

P.70 掲載の参考文献
1) Heidenreich PA, Bozkurt B, Aguilar D et al : 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79 : e263-e421, 2022
 
2) Tsutsui H, Ide T, Ito H et al : JCS/JHFS 2021 Guideline focused update on diagnosis and treatment of acute and chronic heart failure. J Card Fail 27 : 1404-1444, 2021
PubMed
3) Heart failure : an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care, 2022
PubMed
4) Lam CS, Teng TK, Tay WT et al : Regional and ethnic differences among patients with heart failure in Asia : the Asian sudden cardiac death in heart failure registry. Eur Heart J 37 : 3141-3153, 2016
PubMed
5) Fernandez-Real JM, McClain D, Manco M : Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes. Diabetes Care 38 : 2169-2176, 2015
PubMed
6) Shah SR, Ali A, Ikram S : Sotagliflozin and decompensated heart failure : results of the SOLOIST-WHF trial. Expert Rev Clin Pharmacol 14 : 523-525, 2021
PubMed
7) Docherty KF, McMurray JJV : SOLOIST-WHF and updated meta-analysis : sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. Eur J Heart Fail 23 : 27-30, 2021
PubMed
8) Das SR, Everett BM, Birtcher KK et al : 2020 Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes : a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 76 : 1117-1145, 2020
 
9) Nauck MA, Quast DR, Wefers J et al : GLP-1 receptor agonists in the treatment of type 2 diabetes- state-of-the-art. Mol Metab 46 : 101102, 2021
PubMed
10) McAllister DA, Read SH, Kerssens J et al : Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation 138 : 2774-2786, 2018
PubMed
11) Rosengren A, Vestberg D, Svensson AM et al : Long-term excess risk of heart failure in people with type 1 diabetes : a prospective case-control study. Lancet Diabetes Endocrinol 3 : 876-885, 2015
PubMed
P.74 掲載の参考文献
1) Chen IR, Wang SM, Liang CC et al : Association of walking with survival and RRT among patients with CKD stages 3-5. Clin J Am Soc Nephrol 9 : 1183-1189, 2014
PubMed
2) House AA, Haapio M, Lassus J et al : Therapeutic strategies for heart failure in cardiorenal syndromes. Am J Kidney Dis 56 : 759-773, 2010
PubMed
3) Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S et al : Chronic kidney disease as an independent risk for long-term adverse outcomes in patients hospitalized with heart failure in Japan. Report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). Circ J 73 : 1442-1447, 2009
PubMed
4) Damman K, Valente MA, Voors AA et al : Renal impairment, worsening renal function, and outcome in patients with heart failure : an updated meta-analysis. Eur Heart J 35 : 455-469, 2014
PubMed
5) Damman K, Testani JM : The kidney in heart failure : an update. Eur Heart J 36 : 1437-1444, 2015
PubMed
6) Oshima M, Neuen BL, Jardine MJ et al : Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease : a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol 8 : 903-914, 2020
PubMed
7) Cherney DZ, Perkins BA, Soleymanlou N et al : Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 : 587-597, 2014
PubMed
8) Zhang Y, Nakano D, Guan Y et al : A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 94 : 524-535, 2018
 
9) Fang Y, Chen B, Gong AY et al : The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults. Kidney Int 100 : 1037-1053, 2021
 
10) Wanner C, Inzucchi SE, Lachin JM et al : Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 : 323-334, 2016
PubMed
11) Neal B, Perkovic V, Mahaffey KW et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 : 644-657, 2017
PubMed
12) Dekkers CCJ, Wheeler DC, Sjostrom CD et al : Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and stages 3b-4 chronic kidney disease. Nephrol Dial Transplant 33 : 2005-2011, 2018
PubMed
13) Perkovic V, Jardine MJ, Neal B et al : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 : 2295-2306, 2019
PubMed
14) Wiviott SD, Raz I, Bonaca MP et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 : 347-357, 2019
PubMed
15) Packer M, Anker SD, Butler J et al : Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction : the EMPEROR-Reduced trial. Circulation 143 : 326-336, 2021
 
16) Heerspink HJL, Stefansson BV, Correa-Rotter R et al : Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383 : 1436-1446, 2020
PubMed
17) Chertow GM, Vart P, Jongs N et al : Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol 32 : 2352-2361, 2021
PubMed
18) Nagasu H, Yano Y, Kanegae H et al : Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice : the Japan chronic kidney disease database. Diabetes Care 44 : 2542-2551, 2021
PubMed
P.82 掲載の参考文献
1) Nakamura I, Maegawa H, Tobe K et al : Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes : subgroup analysis of STELLA-LONG TERM. Diabetes Ther 12 : 1359-1378, 2021
PubMed
2) Kambara T, Shibata R, Osanai H et al : Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus. Geriatr Gerontol Int 18 : 108-114, 2018
PubMed
3) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
4) Neal B, Perkovic V, Mahaffey KW et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 : 644-657, 2017
PubMed
5) Wiviott SD, Raz I, Bonaca MP et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 : 347-357, 2019
PubMed
6) Araki E, Tanaka A, Inagaki N et al : Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes : a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetol Int 12 : 1-51, 2020
PubMed
7) Tsutsui H, Ide T, Ito H et al : JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circ J 85 : 2252-2291, 2021
PubMed
8) Kambara T, Shibata R, Osanai H et al : Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure. Ther Adv Cardiovasc Dis 13 : 1753944719894509, 2019
PubMed
9) McMurray JJV, Solomon SD, Inzucchi SE et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
10) Packer M, Anker SD, Butler J et al : Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383 : 1413-1424, 2020
PubMed
11) Anker SD, Butler J, Filippatos G et al : Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status : results from the EMPEROR-Reduced trial. Circulation 143 : 337-349, 2021
PubMed
12) Anker SD, Butler J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
13) Butler J, Packer M, Filippatos G et al : Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43 : 416-426, 2022
PubMed
P.85 掲載の参考文献
1) 糖代謝異常者における循環器病の診断・予防・治療に関するコンセンサスステートメント, 日本循環器学会・日本糖尿病学会合同委員会編. https://www.j-circ.or.jp/cms/wp-content/uploads/2022/01/jcs_jds_statement_20220114.pdf, 2020
 
2) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
3) Neal B, Perkovic V, Mahaffey KW et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 : 644-657, 2017
PubMed
4) Mahaffey KW, Neal B, Perkovic V et al : Canagliflozin for primary and secondary prevention of cardiovascular events : results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation 137 : 323-334, 2018
PubMed
5) Wiviott SD, Raz I, Bonaca MP et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Mod 380 : 347-357, 2019
 
6) Perkovic V, Jardine MJ, Neal B et al : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 : 2295-2306, 2019
PubMed
7) McMurray JJV, Solomon SD, Inzucchi SE et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
8) Packer M, Anker SD, Butler J et al : Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383 : 1413-1424, 2020
PubMed
9) Anker SD, Butler J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
10) 2021年日本循環器学会/日本心不全学会合同ガイドライン フォーカスアップデート版 急性・慢性心不全診療, 2021
 
11) Voors AA, Angermann CE, Teerlink JR et al : The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure : a multinational randomized trial. Nat Med 28 : 568-574, 2022
PubMed
12) Kosiborod MN, Angermann CE, Collins SP et al : Effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure- results from the EMPULSE trial. Circulation, 2022. Online ahead of print
 
13) Schulze PC, Bogoviku J, Westphal J et al : Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation, 2022. Online ahead of print
 
14) Velazquez EJ, Morrow DA, DeVore AD et al : Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380 : 539-548, 2019
PubMed
15) Damman K, Beusekamp JC, Boorsma EM et al : Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 22 : 713-722, 2020
PubMed
P.90 掲載の参考文献
1) McMurray JJV, Solomon SD, Inzucchi SE et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
2) Anker SD, Butler J, Filippatos G et al : Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status : results from the EMPEROR-reduced trial. Circulation 143 : 337-349, 2021
PubMed
3) 2021年JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療, 2021
Medical*Online
4) McDonagh TA, Metra M, Adamo M et al : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
PubMed
5) Heidenreich PA, Bozkurt B, Aguilar D et al : 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145 : e895-e1032, 2022
 
6) Anker SD, Butler J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
7) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
8) Neal B, Perkovic V, Mahaffey KW et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 : 644-657, 2017
PubMed
9) Wiviott SD, Raz I, Bonaca MP et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 : 347-357, 2019
PubMed
10) Bhatt DL, Szarek M, Pitt B et al : Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384 : 129-139, 2021
PubMed
11) Cannon CP, Pratley R, Dagogo-Jack S et al : Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383 : 1425-1435, 2020
PubMed
12) American Diabetes Association : Addendum. 9. Pharmacologic approaches to glycemic treatment : standards of medical care in deabetes-2020. Diabetes Care 2020 ; 43 (suppl. 1) : S98-S110. Diabetes Care 43 : 1979, 2020
 
P.95 掲載の参考文献
1) 日本循環器学会・日本心不全学会合同ガイドライン 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療, 2021
 
2) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
3) Neal B, Perkovic V, Mahaffey KW et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 : 644-657, 2017
PubMed
4) Wiviott SD, Raz I, Bonaca MP et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 : 347-357, 2019
PubMed
5) Perkovic V, Jardine MJ, Neal B et al : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 : 2295-2306, 2019
PubMed
6) Packer M, Anker SD, Butler J et al : Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure : proposal of a novel mechanism of action. JAMA Cardiol 2 : 1025-1029, 2017
PubMed
7) Verma S, Rawat S, Ho KL et al : Empagliflozin increases cardiac energy production in diabetes : novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci 3 : 575-587, 2018
PubMed
8) Lahnwong S, Chattipakorn SC, Chattipakorn N : Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardiovasc Diabetol 17 : 101, 2018
PubMed
9) Lytvyn Y, Bjornstad P, Udell JA et al : Sodium glucose cotransporter-2 inhibition in heart failure : potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136 : 1643-1658, 2017
PubMed

第6章 : SGLT2 阻害薬を使用する際の注意点を探る

P.102 掲載の参考文献
1) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
2) Heerspink HJL, Stefansson BV, Correa-Rotter R et al : Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383 : 1436-1446, 2020
PubMed
3) Committee on the Proper Use of SGLT2 Inhibitors : Recommendations on the proper use of SGLT2 inhibitors. J Diabetes Investig 11 : 257-261, 2020
PubMed
4) Geerlings SE, Brouwer EC, Gaastra W et al : Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli : studies with urine from diabetic and non-diabetic individuals. J Med Microbiol 48 : 535-539, 1999
PubMed
5) Geerlings SE, Stolk RP, Camps MJ et al : Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 23 : 1737-1741, 2000
PubMed
6) Neal B, Perkovic V, Mahaffey KW et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 : 644-657, 2017
PubMed
7) Wiviott SD, Raz I, Bonaca MP et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 : 347-357, 2019
PubMed
8) Puckrin R, Saltiel MP, Reynier P et al : SGLT-2 inhibitors and the risk of infections : a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55 : 503-514, 2018
PubMed
9) Mustea I, Muresian T : Crabtree effect in some bacterial cultures. Cancer 20 : 1499-1501, 1967
PubMed
10) Dave CV, Schneeweiss S, Kim D et al : Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections : a population-based cohort study. Ann Intern Med 171 : 248-256, 2019
PubMed
11) Bersoff-Matcha SJ, Chamberlain C, Cao C et al : Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors : a review of spontaneous postmarketing cases. ANN Intern Med 170 : 764-769, 2019
PubMed
12) Tomita I, Kume S, Sugahara S et al : SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab 32 : 404-419.e406, 2020
 
13) Fralick M, Schneeweiss S, Patorno E : Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376 : 2300-2302, 2017
PubMed
14) Goldenberg RM, Gilbert JD, Hramiak IM et al : Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis : the STOP DKA Protocol. Diabetes Obes Metab 21 : 2192-2202, 2019
 
15) Ogawa W, Sakaguchi K : Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors : possible mechanism and contributing factors. J Diabetes Investig 7 : 135-138, 2016
PubMed
16) Kitada K, Kidoguchi S, Nakano D et al : Sodium/glucose cotransporter 2 and renoprotection : from the perspective of energy regulation and water conservation. J Pharmacol Sci 147 : 245-250, 2021
PubMed
17) Cai X, Yang W, Gao X et al : The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients : a meta-analysis. Obesity (Silver Spring) 26 : 70-80, 2018
 
18) Bolinder J, Ljunggren O, Kullberg J et al : Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97 : 1020-1031, 2012
PubMed
19) Boiinder J, Ljunggren O, Johansson L et al : Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16 : 159-169, 2014
 
20) Osonoi T, Nakamoto S. Saito M et al : Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control : a subgroup analysis based on patient characteristics. J Diabetes Investig 9 : 341-353, 2018
PubMed
21) Sasaki T, Sugawara M, Fukuda M : Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile : 52-week prospective LIGHT (luseogliflozin : the components of weight loss in Japanese patients with type 2 diabetes mellitus) Study. J Diabetes Investig 10 : 108-117, 2019
PubMed
22) Ferrannini G, Hach T, Crowe S et al : Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 : 1730-1735, 2015
PubMed
23) Watts NB, Bilezikian JP, Usiskin K et al : Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101 : 157-166, 2016
PubMed
24) Ketteler M, Block GA, Evenepoel P et al : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline update : what's changed and why it matters. Kidney Int 92 : 26-36, 2017
PubMed
25) Cowan A, Jeyakumar N, Kang Y et al : Fracture risk of sodium-glucose cotransporter-2 inhibitors in chronic kidney disease. Clin J Am Soc Nephrol 17 : 835-842, 2022
PubMed
P.108 掲載の参考文献
1) Sano M, Chen S, Imazeki H et al : Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin : subanalysis of placebo-controlled, double-blind clinical trials. J Diabetes Investig 9 : 638-641, 2018
PubMed
2) Sano M : A new class of drugs for heart failure : SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol 71 : 471-476, 2018
 
3) Sano M, Goto S : Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 139 : 1985-1987, 2019
PubMed
4) Sano M : A paradigm shift in the treatment of type 2 diabetes and heart failure. J Atheroscler Thromb 27 : 727-731, 2020
 
5) Sano M : Sodium glucose cotransporter (SGLT) -2 inhibitors alleviate the renal stress responsible for sympathetic activation. Ther Adv Cardiovasc Dis 14 : 1753944720939383, 2020
PubMed
6) Sano M : Inter-organ communication pathway manifested by non-physiological stress to the kidney in type II diabetic patients- why are diabetic patients prone to develop heart failure? Intern Med 59 : 1-5, 2020
 
7) Packer M, Anker SD, Butler J et al : Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure : proposal of a novel mechanism of action. JAMA Cardiol 2 : 1025-1029, 2017
PubMed
8) Shirakawa K, Sano M : Sodium-glucose co-transporter 2 inhibitors correct metabolic maladaptation of proximal tubular epithelial cells in high-glucose conditions. Int J Mol Sci 21 : 7676, 2020
PubMed
9) Schrier RW, Abraham WT : Hormones and hemodynamics in heart failure. N Engl J Med 341 : 577-585, 1999
PubMed
10) Anker SD, Butler J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
11) Schiattarella GG, Altamirano F, Tong D et al : Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568 : 351-356, 2019
PubMed
12) Solomon SD, Vaduganathan M, L Claggett B et al : Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141 : 352-361, 2020
PubMed
13) Butler J, Packer M, Filippatos G et al : Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43 : 416-426, 2022
PubMed
14) Bassi NS, Ziaeian B, Yancy CW et al : Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol 5 : 948-951, 2020
PubMed
15) Vaduganathan M, Claggett BL, Jhund PS et al : Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction : a comparative analysis of three randomised controlled trials. Lancet 396 : 121-128, 2020
PubMed
16) Greene SJ, Khan MS : Quadruple medical therapy for heart failure : medications working together to provide the best care. J Am Coll Cardiol 77 : 1408-1411, 2021
 
P.113 掲載の参考文献
1) Vukadinovic D, Abdin A, Anker SD et al : Side effects and treatment initiation barriers of SGLT2 inhibitors in heart failure : a systematic review and meta-analysis. Eur J Heart Fail, 2022. Online ahead of print
 
2) Younes AM, Salem M, Maraey A et al : Safety outcomes of SGLT2i in the heart failure trials : a systematic review and meta-analysis. Int J Cardiol, 2022. Online ahead of print
 
3) Yokote K, Terauchi Y, Nakamura I et al : Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER) : final results of a post-marketing surveillance study. Expert Opin Pharmacother 17 : 1995-2003, 2016
PubMed
4) Butler J, Usman MS, Khan MS et al : Efficacy and safety of SGLT2 inhibitors in heart failure : systematic review and meta-analysis. ESC Heart Fail 7 : 3298-3309, 2020
PubMed
5) Li X, Zhang Q, Zhu L et al : Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure : a meta-analysis of randomized controlled trials. Int J Cardiol 332 : 119-126, 2021
 
6) Zannad F, Ferreira JP, Pocock SJ et al : SGLT2 inhibitors in patients with heart failure with reduced ejection fraction : a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396 : 819-829, 2020
PubMed
7) Butt JH, Dewan P, Merkely B et al : Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction : a post hoc analysis of the DAPA-HF trial. Ann Intern Med 175 : 820-830, 2022
PubMed
8) Mone P, Lombardi A, Gambardella J et al : Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care 45 : 1247-1251, 2022
 
P.119 掲載の参考文献
1) Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S et al : Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70 : 1617-1623, 2006
PubMed
2) McMurray JJV, Solomon SD, Inzucchi SE et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
3) Packer M, Anker SD, Butler J et al : Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383 : 1413-1424, 2020
PubMed
4) Anker SD, Butler J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
5) Heerspink HJL, Stefansson BV, Correa-Rotter R et al : Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383 : 1436-1446, 2020
PubMed
6) Perkovic V, Jardine MJ, Neal B et al : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 : 2295-2306, 2019
PubMed
7) EMPA-KIDNEY Collaborative Group : Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 37 : 1317-1329, 2022
 
8) Meraz-Munoz AY, Weinstein J, Wald R : eGFR decline after SGLT2 inhibitor initiation : the tortoise and the hare reimagined. Kidney 360 2 : 1042-1047, 2021
PubMed
9) Xie Y, Bowe B, Gibson AK et al : Clinical implications of estimated glomerular filtration rate dip following sodiurn-glucose cotransporter-2 inhibitor initiation on cardiovascular and kidney outcomes. J Am Heart Assoc 10 : e020237, 2021
PubMed
10) Kraus BJ, Weir MR, Bakris GL et al : Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 99 : 750-762, 2021
PubMed
11) Tamaki S, Yamada T, Watanabe T et al : Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure : a prospective randomized controlled study. Circ Heart Eail 14 : e007048, 2021
 
P.123 掲載の参考文献
1) Anker SD, Bulter J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
 
2) Peters SA, Huxley RR, Woodward M : Diabetes as risk factor for incident coronary heart disease in women compared with men : a systematic review and meta-analysis of 64 cohorts including 858, 507 individuals and 28,203 coronary events. Diabetologia 57 : 1542-1551, 2014
 
3) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
4) Radholm K, Zhou Z, Clemens K et al : Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab 22 : 263-266, 2020
PubMed
5) Butt JH, Docherty KF, Petrie MC et al : Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction : a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial. JAMA Cardiol 6 : 678-689, 2021
PubMed
6) フォシーガ錠 発売開始1年後 安全性結果報告
 
7) ジャディアンス錠 市販後調査報告
 
8) Fournier JA : Gangrene foudroyante de la verge. Sem Med 3 : 345-348, 1883
 
9) 野田昌宏, 盛真一郎, 出先亮介ほか : フルニエ壊疽の重症度評価法と治療法に関する検討. 日本腹部救急医学会雑誌 34 : 1107-1112, 2014
 
10) Food and Drug Administration : FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm
 

第7章 : SGLT2 阻害薬による心不全治療の今後の展望をみる

P.130 掲載の参考文献
1) Ide T, Kazu H, Matsushima S et al : Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese registry of acute decornpensated heart failure (JROADHF). Circ J 85 : 1438-1450, 2021
 
2) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
3) Wiviott SD, Raz I, Bonaca MP et al : Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 : 347-357, 2019
PubMed
4) McMurray JJV, Solomon SD, Inzucchi SE et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
5) Packer M, Anker SD, Butler J et al : Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383 : 1413-1424, 2020
PubMed
6) Verma S, Rawat S, Ho KL et al : Empagliflozin increases cardiac energy production in diabetes : novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci 3 : 575-587, 2018
PubMed
7) Lahnwong S, Chattipakorn SC, Chattipakorn N : Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardiovasc Diabetol 17 : 101, 2018
PubMed
8) Farkouh ME, Verma S : Prevention of heart failure with SGLT-2 inhibition : insights from CVD-REAL. J Am Coll Cardiol 71 : 2507-2510, 2018
 
9) Butler J, Fonarow GC, Zile MR et al : Developing therapies for heart failure with preserved ejection fraction : current state and future directions. JACC Heart Fail 2 : 97-112, 2014
PubMed
10) Shah SJ, Borlaug BA, Kitzman DW et al : Research priorities for heart failure with preserved ejection fraction : National Heart, Lung, and Blood Institute working group summary. Circulation 141 : 1001-1026, 2020
 
11) Anker SD, Butler J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
12) Damman K, Beusekamp JC, Boorsma EM et al : Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 22 : 713-722, 2020
PubMed
13) Voors AA, Angermann CE, Teerlink JR et al : The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure : a multinational randomized trial. Nat Med 28 : 568-574, 2022
PubMed
14) Vasilakou D, Karagiannis T, Athanasiadou E et al : Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes : a systematic review and meta-analysis. Ann Intern Med 159 : 262-274, 2013
PubMed
15) Yabe D, Iwasaki M, Kuwata H et al : Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes : a randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab 19 : 739-743, 2017
 
P.135 掲載の参考文献
1) Kosiborod MN, Jhund PS, Docherty KF et al : Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction : results from the DAPA-HF trial. Circulation 141 : 90-99, 2020
PubMed
2) Butler J, Anker SD, Filippatos G et al : Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction : the EMPEROR-reduced trial. Eur Heart J 42 : 1203-1212, 2021
PubMed
3) Butler J, Filippatos G, Jamal Siddiqi T et al : Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction : the EMPEROR-preserved trial. Circulation 145 : 184-193, 2022
PubMed
4) Butt JH, Dewan P, Merkely B et al : Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction : a post hoc analysis of the DAPA-HF trial. Ann Intern Med, 2022. Online ahead of print
 
P.140 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 2021年JCS/JHFSガイドラインフォーカスアップデート版, 急性・慢性心不全診療 http://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf
 
2) Lopaschuk GD, Verma S : Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors : a state-of-the-art review. JACC Basic Transl Sci 5 : 632-644, 2020
PubMed
3) Green CP, Porter CB, Bresnahan DR et al : Development and evaluation of the Kansas City Cardiomyopathy Questionnaire : a new health status measure for heart failure. J Am Coll Cardiol 35 : 1245-1255, 2000
PubMed
4) Parissis JT, Nikolaou M, Farmakis D et al : Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure. Eur J Heart Fail 11 : 163-169, 2009
PubMed
5) Pokharel Y, Khariton Y, Tang Y et al : Association of serial Kansas City Cardiomyopathy Questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction : a secondary analysis of 2 randomized clinical trials. JAMA Cardiol 2 : 1315-1321, 2017
PubMed
6) McMurray JJV, Solomon SD, Inzucchi SE et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
7) Packer M, Anker SD, Butler J et al : Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383 : 1413-1424, 2020
PubMed
8) Kosiborod MN, Jhund PS, Docherty KF et al : Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction : results from the DAPA-HF trial. Circulation 141 : 90-99, 2020
PubMed
9) Butler J, Anker SD, Filippatos G et al : Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction : the EMPEROR-reduced trial. Eur Heart 142 : 1203-1212, 2021
 
10) He Z, Yang L, Nie Y et al : Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction : a systematic review and meta-analysis. Int J Cardiol 345 : 83-88, 2021
 
11) Anker SD, Butler J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
12) Butler J, Filippatos G, Jamal Siddiqi T et al : Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction : the EMPEROR-preserved trial. Circulation 145 : 184-193, 2022
PubMed
13) Abraham WT, Lindenfeld J, Ponikowski P et al : Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J 42 : 700-710, 2021
PubMed
14) Bhatt DL, Szarek M, Steg PG et al : Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384 : 117-128, 2021
PubMed
15) Kosiborod MN, Angermann CE, Collins SP et al : Effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure-results from the EMPULSE trial. Circulation, 2022. Online ahead of print
 
16) Ferrannini E, Baldi S, Frascerra S et al : Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65 : 1190-1195, 2016
PubMed
17) SGLT2阻害薬の適正使用に関する委員会 : SGLT2阻害薬の適正使用に関するRecommendation. http://www.fa.kyorin.co.jp/jds/uploads/recommendation_SGLT2.pdf, 2020年12月25日改訂
 
P.146 掲載の参考文献
1) McMurray JJV, Solomon SD, Inzucchi SE et al : Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med 381 : 1995-2008, 2019
PubMed
2) Packer M, Anker SD, Butler J et al : Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383 : 1413-1424, 2020
PubMed
3) 2021年JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療, 2021
Medical*Online
4) McDonagh TA, Metra M, Adamo M et al : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
PubMed
5) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure : a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145 : e895-e1032, 2022
 
6) Fontes-Carvalho R, Santos-Ferreira D, Raz I et al : Protective effects of SGLT-2 inhibitors across the cardiorenal continuurn : two faces of the same coin. Eur J Prev Cardiol, 2021, Online ahead of print
 
7) Anker SD, Butler J, Filippatos G et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
8) Voors AA, Angermann CE, Teerlink JR et al : The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure : a multinational randomized trial. Nat Med 28 : 568-574, 2022
PubMed
9) Schulze PC, Bogoviku J, Westphal J et al : Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation, 2022, Online ahead of print
 
10) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, cardiovascular outcomes, and mortahty in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
11) Neal B, Perkovic V, Mahaffey KW et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 : 644-657, 2017
PubMed
12) Wiviott SD, Raz I, Bonaca MP et al : Dapagliflozin and cardiovascular outcornes in type 2 diabetes. N Engl J Med 380 : 347-357, 2019
PubMed
13) American Diabetes Association : 9. Pharmacologic approaches to glycemic treatment : standards of medical care in diabetes-2021. Diabetes Care 44 : S111-S124, 2021
PubMed
14) Perkovic V, Jardine MJ, Neal B et al : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 : 2295-2306, 2019
PubMed
15) Heerspink HJL, Stefansson BV, Correa-Rotter R et al : Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383 : 1436-1446, 2020
PubMed
16) Herrington WG, Preiss D, Haynes R et al : The potential for improving cardio-renal outcomes by sodiurn-glucose co-transporter-2 inhibition in people with chronic kidney disease : a rationale for the EMPA-KIDNEY study. Clin Kidney J 11 : 749-761, 2018
PubMed
17) van der Aart-van der Beek AB, de Boer RA, Heerspink HJL : Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 18 : 294-306, 2022
PubMed
18) Writing Committee, Maddox TM, Januzzi JL Jr et al : 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment : Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction : A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 77 : 772-810, 2021
 

書評

最近チェックした商品履歴

Loading...